Tagadtal, Husain M.

HRN: 21-51-02  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/24/2022
CEFUROXIME 1.5GM (VIAL)
06/24/2022
06/30/2022
IVTT
1.5
Q8
TB Spondylodiscitis
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bone & JointMultiple Infections (tick All Sites)    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: